Dendritic Mesoporous Silica Nanoparticles for pH-Stimuli-Responsive Drug Delivery of TNF-Alpha

Adv Healthc Mater. 2017 Jul;6(13). doi: 10.1002/adhm.201700012. Epub 2017 May 29.

Abstract

Tumor necrosis factor-alpha (TNF-α) is a pleiotropic immune stimulatory cytokine and natural endotoxin that can induce necrosis and regression in solid tumors. However, systemic administration of TNF-α is not feasible due to its short half-life and acute toxicity, preventing its widespread use in cancer treatment. Dendritic mesoporous silica nanoparticles (DMSN) are used coated with a pH-responsive block copolymer gate system combining charged hyperbranched polyethylenimine and nonionic hydrophilic polyethylenglycol to encapsulate TNF-α and deliver it into various cancer cell lines and dendritic cells. Half-maximal effective concentration (EC50 ) for loaded TNF-α is reduced by more than two orders of magnitude. Particle stability and premature cargo release are assessed with enzyme-linked immunosorbent assay. TNF-α-loaded particles are stable for up to 5 d in medium. Tumor cells are grown in vitro as 3D fluorescent ubiquitination-based cell cycle indicator spheroids that mimic in vivo tumor architecture and microenvironment, allowing real-time cell cycle imaging. DMSN penetrate these spheroids, release TNF-α from its pores, preferentially affect cells in S/G2/M phase, and induce cell death in a time- and dose-dependent manner. In conclusion, DMSN encapsulation is demonstrated, which is a promising approach to enhance delivery and efficacy of antitumor drugs, while minimizing adverse side effects.

Keywords: mesoporous silica nanoparticles; pH-triggered release; proinflammatory cytokine; stimuli-responsive drug delivery; tumor necrosis factor-alpha.

MeSH terms

  • Cell Cycle / drug effects*
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems / methods*
  • Humans
  • Nanoparticles* / chemistry
  • Nanoparticles* / therapeutic use
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Porosity
  • Silicon Dioxide* / chemistry
  • Silicon Dioxide* / pharmacokinetics
  • Silicon Dioxide* / pharmacology
  • Tumor Necrosis Factor-alpha* / chemistry
  • Tumor Necrosis Factor-alpha* / pharmacokinetics
  • Tumor Necrosis Factor-alpha* / pharmacology

Substances

  • Tumor Necrosis Factor-alpha
  • Silicon Dioxide